Publications by authors named "A Robidoux"
Purpose: To determine, in women with primary operable breast cancer, if preoperative doxorubicin (Adriamycin) and cyclophosphamide (Cytoxan; AC) therapy yields a better outcome than postoperative AC therapy, if a relationship exists between outcome and tumor response to preoperative chemotherapy, and if such therapy results in the performance of more lumpectomies.
Patients And Methods: Women (1,523) enrolled onto National Surgical Adjuvant Breast and Bowel Project (NSABP) B-18 were randomly assigned to preoperative or postoperative AC therapy. Clinical tumor response to preoperative therapy was graded as complete (cCR), partial (cPR), or no response (cNR).
The nematode Caenorhabditis elegans utilizes chemosensation to navigate an ever-changing environment for its survival. A class of secreted small-molecule pheromones, termed ascarosides, play an important role in olfactory perception by affecting biological functions ranging from development to behavior. The ascaroside #8 (ascr#8) mediates sex-specific behaviors, driving avoidance in hermaphrodites and attraction in males.
View Article and Find Full Text PDFBackground: The 21-gene Breast Recurrence Score (RS) assay, "the assay", has led to a paradigm shift for patients with hormone receptor-positive, node-negative early breast cancer and is emerging as an important tool to assist physician-patient decisions in foregoing chemotherapy in node-positive patients. We wanted to better understand the impact of the RS assay in node-positive patients upon physician treatment decisions and treatment cost in Quebec, Canada.
Patients And Methods: We conducted a multicenter, prospective observational trial for Estrogen/Progesterone Receptor (ER/PR)- positive, Human Epidermal Growth Factor Receptor 2 (HER2)-negative breast cancer patients with 1-3 positive lymph nodes.
Article Synopsis
- The NSABP B-36 trial compared the effectiveness of 6 cycles of epirubicin-based chemotherapy (FEC-100) to 4 cycles of doxorubicin-based chemotherapy (AC) in women with node-negative invasive breast cancer.
- Results showed no significant improvement in disease-free survival (DFS) with FEC-100 over AC, despite higher toxicity reported in the FEC-100 group.
- Additionally, the treatment's effectiveness varied by hormone receptor status, with FEC-100 performing better in receptor-positive patients, but overall, the findings do not support using prolonged anthracycline regimens for this patient group.